CDTX
SHORT13D FILEDCidara Therapeutics Inc
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
NeutralCDTX ceased to exist as a public company on January 7, 2026, following Merck's completion of a $9.2 billion acquisition at $221.50/share. The deal hinges on CD388 (rebranded MK-1406), a Phase 3 antiviral with $5B+ revenue potential; the ANCHOR trial reached target enrollment of 6,000 participants with interim analysis in Q1 2026 and primary completion expected January 2027, positioning potential market entry in 2028.
Red flags
- •No public equity security exists post-January 7, 2026 — all investment exposure now embedded in Merck stock and subject to Merck's integration execution
- •MK-1406 market entry delayed to 2028 at earliest; Phase 3 efficacy results not yet disclosed, creating binary outcome risk
- •$9.0B acquisition expense will reduce Merck's 2026 GAAP/non-GAAP EPS by ~$0.30, creating near-term earnings headwind for Merck shareholders
- •Single Phase 3 trial (ANCHOR) is sole pathway to BLA approval; no backup trial data provides concentration risk on one clinical readout
Funds Reducing / Exiting (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | 0 | −49K | — | 0.3% | -100% | EXITED |
| Soros Fund Management | Soros Family Office | 0 | −275K | — | 0.8% | -100% | EXITED |
| Maverick Capital | Lee Ainslie | 0 | −456K | — | 1.1% | -100% | EXITED |
| Point72 | Steve Cohen | 0 | −250K | — | 0.3% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | SC 13G/A | 450K | 1.4% | 2026-02-17 | ↗ |
| BCLS Fund III Investments, LP | SC 13G/A | — | 0.0% | 2026-02-17 | ↗ |
| Vivo Opportunity Fund Holdings, L.P. | SC 13G/A | — | 0.0% | 2026-02-13 | ↗ |
| The Vanguard Group | SC 13G | 2.0M | 6.4% | 2026-01-30 | ↗ |
| RA Capital Management, L.P. | SC 13D/A | — | 0.0% | 2026-01-09 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.